FSD Pharma Inc. (HUGE)
| Previous close | 0.4740 |
| Open | 0.4700 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.4700 - 0.5000 |
| 52-week range | 0.4180 - 1.6800 |
| Volume | |
| Avg. volume | 168,175 |
| Market cap | 19.916M |
| Beta (5Y monthly) | 0.91 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.4600 |
| Earnings date | 10 May 2024 - 14 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireGBB Maintains Strong Position in its Ongoing Lawsuit with FSD Pharma After Court Refuses to Dismiss Case
The Court concludes that Plaintiff has sufficiently demonstrated that its trade secrets derived economic value from not being readily ascertainable by othersWESTON, Fla., Jan. 11, 2024 (GLOBE NEWSWIRE) -- GBB Drink Lab. Inc (“GBB” or the “Company”), a maker of the world’s first rapid blood alcohol detoxification beverage, is pleased to announce that a federal court has refused to dismiss the Company’s ongoing lawsuit against FSD Pharma. FSD Pharma (NASDAQ: HUGE), a clinical-stage biotech company
GlobeNewswireInvestmentPitch Media Video Discusses FSD Pharma’s Continued Development of its Exciting New Rapid Detox Drink UNBUZZD™, with Video Comments from Kevin Harrington
VANCOUVER, British Columbia, Sept. 22, 2023 (GLOBE NEWSWIRE) -- FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FSE:0K9A), a biotechnology company building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, continues with the development of its exciting new rapid detox drink UNBUZZD™. Today, we’re following up on our August 2nd feature video in which we discussed UNBUZZD™, a proprietary formulation of natural
Business WireFSD Pharma Rebuts Claims of GBB Drink Lab now acquired by Jupiter Wellness Inc. Trading under the symbol (NASDAQ: JUPW)
TORONTO, August 25, 2023--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders, today provides clarity and rebuttal to frivolous claims disparaging the Company and its groundbreaking efforts relating to its development of an innovative rapid alcohol detoxification drink, using its pro
